SCHEMBL23997484

SCHEMBL23997484

O=[N+]([O-])c1cc(Cl)ccc1NCc1ccc(Cc2nnco2)cc1

nearest known ligand 0.61

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 12/20 0.61
▸ L3MBTL1 Q9Y468 3/20 0.61
▸ TDP1 Q9NUW8 2/20 0.61
▸ CYP1A2 P05177 2/20 0.46
▸ CYP3A4 P08684 2/20 0.46
▸ CYP2C19 P33261 2/20 0.46
▸ CYP2D6 P10635 1/20 0.46
▸ CYP2C9 P11712 1/20 0.46
▸ POLB P06746 1/20 0.46
▸ SMN1; SMN2 Q16637 1/20 0.46
▸ MEN1 O00255 2/20 0.45
▸ KMT2A Q03164 2/20 0.45
▸ ALDH1A1 P00352 3/20 0.45
▸ NPSR1 Q6W5P4 1/20 0.45
▸ LMNA P02545 1/20 0.43
▸ HTT P42858 1/20 0.43
▸ PKM P14618 1/20 0.43
▸ HPGD P15428 1/20 0.41
▸ HTR6 P50406 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9683242 0.81 MAPT (0.84) MAPTL3MBTL1TDP1CYP1A2CYP3A4
SCHEMBL23997423 0.81 MAPT (0.35) MAPTL3MBTL1TDP1POLBPKM
SCHEMBL9681781 0.76 MAPT (0.71) MAPTL3MBTL1TDP1CYP1A2CYP3A4
SCHEMBL9682067 0.76 MAPT (0.76) MAPTL3MBTL1TDP1CYP1A2CYP3A4
SCHEMBL2465858 0.76 MAPT (0.75) MAPTL3MBTL1TDP1CYP1A2CYP3A4
SCHEMBL9681394 0.73 MAPT (0.74) MAPTL3MBTL1TDP1CYP1A2CYP3A4
SCHEMBL9701292 0.73 MAPT (0.74) MAPTL3MBTL1TDP1CYP1A2CYP3A4
SCHEMBL30578709 0.72 KMT2A (0.44) MAPTTDP1CYP1A2CYP3A4CYP2C19
SCHEMBL4836703 0.71 POLB (0.51) MAPTCYP1A2CYP2C19CYP2C9POLB
SCHEMBL9682260 0.71 MAPT (0.67) MAPTL3MBTL1TDP1CYP1A2CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12454525-B2 IL4I1 inhibitors and methods of use MERCK SHARP & DOHME LLC (US) 2025-10-28 — — US disclosed
CN-115836054-B IL4I1 inhibitors and methods of use 默沙东有限责任公司 2024-12-10 — — CN disclosed
US-20230183214-A1 IL4I1 INHIBITORS AND METHODS OF USE MERCK SHARP & DOHME LLC 2023-06-15 — — US disclosed
US-20230183214-A1 IL4I1 INHIBITORS AND METHODS OF USE MERCK SHARP & DOHME LLC 2023-06-15 — — US disclosed
CN-115836054-A IL4I1 inhibitors and methods of use 默沙东有限责任公司 2023-03-21 — — CN disclosed
WO-2021226003-A1 IL4I1 INHIBITORS AND METHODS OF USE MERCK SHARP & DOHME CORP. (US) 2021-11-11 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230183214-A1 IL4I1 INHIBITORS AND METHODS OF USE IL4I1, IL4, IL2 MAPT 3407/4885L3MBTL1 4116/4885TDP1 4265/4885
US-12454525-B2 IL4I1 inhibitors and methods of use IL4I1, IL4, IL2 MAPT 3407/4885L3MBTL1 4116/4885TDP1 4265/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback